Key result
Rosuvastatin therapy for 18 months improved flow-mediated vasodilation from 7.10% at baseline to 8.70% at study end in patients with inflammatory joint diseases.
Why the study?
Does rosuvastatin improve endothelial function in statin-naïve patients with inflammatory joint diseases and established atherosclerosis?
Does rosuvastatin improve endothelial function in statin-naïve patients with inflammatory joint diseases and established atherosclerosis?
Long-term rosuvastatin therapy improves endothelial function and is associated with reduced arterial stiffness and carotid plaque regression in patients with inflammatory joint diseases.
Answers are grounded in this paper and cite their sources.
May support endothelial benefits of long-term rosuvastatin in inflammatory joint diseases; hypothesis-generating pending randomized outcome trials.
INTRODUCTION: Endothelial dysfunction is an early step in the atherosclerotic process and can be quantified by flow-mediated vasodilation (FMD). Our aim was to investigate the effect of long-term rosuvastatin therapy on endothelial function in patients with inflammatory joint diseases (IJD) with established atherosclerosis. Furthermore, to evaluate correlations between change in FMD (ΔFMD) and change in carotid plaque (CP) height, arterial stiffness [aortic pulse wave velocity (aPWV) and augmentation index (AIx)], lipids, disease activity and inflammation. METHODS: Eighty-five statin-naïve patients with IJD and ultrasound-verified CP (rheumatoid arthritis: n = 53, ankylosing spondylitis: n = 24, psoriatic arthritis: n = 8) received rosuvastatin treatment for 18 months. Paired-samples t tests were used to assess ΔFMD from baseline to study end. Linear regression models were applied to evaluate correlations between ∆FMD and cardiovascular risk factors, rheumatic disease variables and medication. RESULTS: The mean ± SD FMD was significantly improved from 7.10 ± 3.14 % at baseline to 8.70 ± 2.98 % at study end (p < 0.001). Improvement in AIx (p < 0.05) and CP height reduction (p = 0.001) were significantly associated with ΔFMD (dependent variable). CONCLUSIONS: Long-term lipid lowering with rosuvastatin improved endothelial function in IJD patients with established atherosclerotic disease. Reduced arterial stiffness and CP regression were longitudinally correlated with the improvement in endothelial function measured by FMD. TRIAL REGISTRATION: ClinicalTrials.gov NCT01389388 . Registered 16 April 2010.
No takes yet. Share an insight, caveat, or question.
Ikdahl et al. (2015) studied Inflammatory joint diseases with established atherosclerosis (n=85). Rosuvastatin vs. Baseline was evaluated on Flow-mediated vasodilation (FMD) (p=<0.001). Rosuvastatin therapy for 18 months improved flow-mediated vasodilation from 7.10% at baseline to 8.70% at study end in patients with inflammatory joint diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: